乳腺癌病人血清her2-neu检测及其临床意义.docVIP

乳腺癌病人血清HER2/neu检测及其临床意义 nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp;nbsp; 作者：朱美琴， 滕小玉， 姜文奇， 刘冬耕， 张东生， 周宁宁nbsp;nbsp; 【摘要】nbsp; 【目的】 本研究分析晚期乳腺癌患者血清HER-2/neu的水平与预后的关系，并探讨其临床意义。【方法】 酶联免疫法（ELISA）检测94例晚期乳腺癌患者血清HER-2/neu的浓度，分析血清与组织中HER-2/neu表达的相关性，并分析其与患者预后的关系。【结果】 94例晚期乳腺癌患者就诊时的血清HER-2/neu浓度为0.34～275.25 ?滋g/L（平均浓度为23.69 ?滋g/L）。血清HER-2/neu浓度的高低与化疗的有效性、疾病进展时间的长短无关。晚期乳腺癌患者的血清HER-2/neu浓度与肿瘤组织中HER-2/neu表达强阳性是一致的。【结论】 血清HER-2/neu尚不能确立为独立的预后指标，需要更多的病例进行分析。 【关键词】nbsp; 乳腺肿瘤； 血清HER-2/neu； 酶联吸附法； 预后 nbsp;nbsp;nbsp; Abstract:【Objective】 This study was to analyze the relationship between the serum HER-2/neu protein levels and prognosis in advanced breast cancer patients. 【Methods】 The serum HER-2/neu protein levels of 94 advanced breast cancer patients were detected using ELISA method. The relationship between the protein level and patient prognosis were analyzed retrospectively. Besides, the consistency of expression in serum and tissue was also analyzed. 【Results】 The concentrations of serum HER-2/neu were 0.34 μg/L to 275.25 μg/L (mean 23.69 μg/L). HERe was no correlation between serum HER-2/neu levels and time to progress (TTP). In addition, the level of serum HER-2/neu was concordance with strong expression of HER-2/neu in tumor tissue in advanced breast cancer. 【Conclusion】The clinical utility of serum HER-2/neu as a prognostic indicator has not yet been established and needs more cases to evaluate. nbsp;nbsp;nbsp; Key words: breast neoplasm; serum HER-2/neu; enzyme-linked immunosorbnent assay（ELISA）; prognosis nbsp;nbsp;nbsp; ［J SUN Yat-sen Univ(Med Sci), 2007, 28（6）:678-682］ nbsp;nbsp;nbsp; 乳腺癌已成为女性最常见的恶性肿瘤，也是常见的女性肿瘤死亡原因[1]。大约有20％～30％的乳腺癌患者HER-2/neu高表达, HER-2/neu高表达与患者的不良预后密切相关[2]。HER-2/neu基因是人表皮生长因子家族的第2位成员。定位于染色体17q21，其编码一种分子量为185 ku的跨膜糖蛋白，具有酪氨酸激酶活性，结构上分为膜外配体结合域、跨膜区和膜内酪氨酸激酶的活性域[3]。HER-2/neu蛋白的胞外部分可以从细胞的表面脱落至血液中，形成分子量大约为105 ku的可溶性蛋白HER-2ECD。这种可溶性蛋白可以用酶联免疫吸附试验（enzyme-linked immunosorbnent assay，ELISA）测定[4]。我们用ELISA